As the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...

As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...

Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...

India's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...

We are in a phase in the US-Israel-Iran war where statements are made, then retracted. And, in a matter of just 48 hours, they are made all...

There are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...

The landscape of India's anti-obesity drug market has reached a point of refinement. While there are affordable generic options, their upta...

Private equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per sha...

A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...

When mid-caps were rising, every concern on valuation was treated as unnecessary caution. Investors who advised patience were told they wer...

Just look at developments in the past 48 hours. The war between Iran and Israel resumed, but within hours Tehran said it had halted all off...

Even in normal times it is futile to try and guess the outcome of most global events. But in the New World Order, it makes no sense at all ...

At a time when there are so many headwinds for the markets, it is tough to imagine that things can get better. But sentiment is a fickle th...

India targets $30 billion in seafood exports within five years. This ambitious goal involves increasing production and quality. The nation ...

Investor Tom Gayner views stocks as ownership in businesses built on human ingenuity. He emphasizes that a company's value stems from its i...

There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...